Healio (5/29) reported that on May 28, the FDA “announced the approval of Tauvid [flortaucipir F18], an IV injection that is used to help image a specific characteristic of Alzheimer’s disease in the brain known as tau pathology.” The agency has approved Tauvid for “adults who have cognitive impairment and are being evaluated for Alzheimer’s disease, according to an FDA press release.” Tauvid “is a radioactive diagnostic agent that is indicated for positron emission tomography imaging of the brain” that is “used to assess the density and distribution of aggregated tau neurofibrillary tangles…which is a primary signal of Alzheimer’s disease, the release said.”
Medscape (5/29, Brooks, Subscription Publication) reported, “Treatment with the antidepressant bupropion does not improve apathy in nondepressed patients with dementia of Alzheimer type,” researchers concluded in a 108-patient, “multicenter, double-blind, placebo-controlled trial,” investigators found. Even though the medication is “safe in this patient population, bupropion was no better than placebo in reducing apathy, neuropsychiatric symptoms, or health-related quality of life, the researchers say.” The findings were published online May 28 in JAMA Network Open
